MarketPulse

non-muscle invasive bladder cancer

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Urogen Pharma Ltd.

Bladder Cancer Survey Reveals High Recurrence Fear, Procedural Burden Among Patients

BCAN survey of 1,100+ bladder cancer patients shows 80% experience recurrence fear, exceeding 90% in under-50 cohort. UroGen emphasizes need for treatments balancing tumor control with quality of life.
URGNquality of lifebladder cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Protara Posts $57.4M Annual Loss as TARA-002 Bladder Cancer Data Bolsters Pipeline

Protara Therapeutics reported $57.4M full-year 2025 loss while unveiling promising 68% response rate for TARA-002 in bladder cancer trial with funding extending to 2028.
TARAfinancial resultsclinical trial